

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2019/169219 A1

(43) International Publication Date
06 September 2019 (06.09.2019)

(51) International Patent Classification:

A61K 31/454 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/517 (2006.01) *A61K 38/21* (2006.01)

(21) International Application Number:

PCT/US2019/020201

(22) International Filing Date:

01 March 2019 (01.03.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/637,981 02 March 2018 (02.03.2018) US

(71) Applicant: **IONIS PHARMACEUTICALS, INC.**
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **ZHAO, Tianyuan**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **KIM, Youngsoo**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **MACLEOD, Robert**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **BUI, Huynh-Hoa**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **FREIER, Susan, M.**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US).

(74) Agent: **TAYLOR, Kerry, S.** et al.; Knobbe Martens LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MODULATORS OF IRF4 EXPRESSION

(57) Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.

WO 2019/169219 A1